A Three-part, Partially Open Label and Double-blind, Randomized Study to Assess the Pharmacodynamic Effects, Safety, Tolerability and Preliminary Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome Using [Zr-89]-Rituximab PET/CT

Trial Profile

A Three-part, Partially Open Label and Double-blind, Randomized Study to Assess the Pharmacodynamic Effects, Safety, Tolerability and Preliminary Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome Using [Zr-89]-Rituximab PET/CT

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs VAY 736 (Primary) ; Rituximab
  • Indications Sjogren's syndrome
  • Focus Diagnostic use; Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 03 Feb 2016 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017, according to ClinicalTrials.gov record.
    • 03 Feb 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017, according to ClinicalTrials.gov record.
    • 03 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top